The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Reduced oxidative damage in ALS by high‐dose enteral melatonin treatment
Open accessAbstract
Amyotrophic lateral sclerosis (ALS) is the collective term for a fatal motoneuron disease of different etiologies, with oxidative stress as a common molecular denominator of disease progression. Melatonin is an amphiphilic molecule with a unique spectrum of antioxidative effects not conveyed by classical antioxidants. In preparation of a possible future clinical trial, we explored the potential of melatonin as neuroprotective compound and antioxidant in: (1) cultured motoneuronal cells (NSC‐34), (2) a genetic mouse model of ALS (SOD1 G93A‐transgenic mice), and (3) a group of 31 patients with sporadic ALS. We found that melatonin attenuates glutamate‐induced cell death of cultured motoneurons. In SOD1 G93A‐transgenic mice, high‐dose oral melatonin delayed disease progression and extended survival. In a clinical safety study, chronic high‐dose (300 mg/day) rectal melatonin was well tolerated during an observation period of up to 2 yr. Importantly, circulating serum protein carbonyls, which provide a surrogate marker for oxidative stress, were elevated in ALS patients, but were normalized to control values by melatonin treatment. This combination of preclinical effectiveness and proven safety in humans suggests that high‐dose melatonin is suitable for clinical trials aimed at neuroprotection through antioxidation in ALS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
[49] Determination of carbonyl content in oxidatively modified proteins
Levine, R. L., Garland, D., Oliver, C. N., Amici, A., Climent, I., Lenz, A.-G., Ahn, B.-W., Shaltiel, S., & Stadtman, E. R. (1990) · Methods in Enzymology · doi:10.1016/0076-6879(90)86141-h · Cited by 5,887
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143
Of Mice and Not Men: Differences between Mouse and Human Immunology
Mestas, J., & Hughes, C. C. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2731 · Cited by 3,822 · cited 1×
“Similar differences of disease dynamics have been noted between other transgenic models and their respective human disorders, including Alzheimer’s disease and multiple sclerosis [48, 49].”
Trk Receptors: Roles in Neuronal Signal Transduction
Huang, E. J., & Reichardt, L. F. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161629 · Cited by 2,537 · cited 1×
“Similarly, Western blot analysis of spinal cord protein lysates failed to detect differences in total amount or phosphorylation status of AKT or ERK1/2, kinases involved in the modulation of neuronal cell death [34].”
BackgroundA Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
Bensimon, G., Lacomblez, L., & Meininger, V. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300901 · Cited by 2,233
Regulation of antioxidant enzymes: a significant role for melatonin
Rodriguez, C., Mayo, J. C., Sainz, R. M., Antolín, I., Herrera, F., Martín, V., & Reiter, R. J. (2004) · Journal of Pineal Research · doi:10.1046/j.1600-079x.2003.00092.x · Cited by 1,987
Rowland, L. P., & Shneider, N. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442207 · Cited by 1,812
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518 · cited 2×
“, in combined treatment schemes with riluzole [5, 6], minocycline [57, 58], cephalosporines [60], or possibly COX-2 inhibitors [61].”
BackgroundSelective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis
Rothstein, J. D., Van Kammen, M., Levey, A. I., Martin, L. J., & Kuncl, R. W. (1995) · Annals of Neurology · doi:10.1002/ana.410380114 · Cited by 1,471
Bruijn, L. I., Becher, M. W., Lee, M. K., Anderson, K. L., Jenkins, N. A., Copeland, N. G., Sisodia, S. S., Rothstein, J. D., Borchelt, D. R., Price, D. L., et al. (1997) · Neuron · doi:10.1016/s0896-6273(00)80272-x · Cited by 1,341
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis/Riluzole Study Group II, Lacomblez, L., Bensimon, G., Meininger, V, Leigh, P. N., & Guillet, P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91680-3 · Cited by 1,301
UNRAVELING THE MECHANISMS INVOLVED IN MOTOR NEURON DEGENERATION IN ALS
Bruijn, L. I., Miller, T. M., & Cleveland, D. W. (2004) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.27.070203.144244 · Cited by 1,185
Zhu, S., Stavrovskaya, I. G., Drozda, M., Kim, B. Y. S., Ona, V., Li, M., Sarang, S., Liu, A. S., Hartley, D. M., Wu, D. C., et al. (2002) · Nature · doi:10.1038/417074a · Cited by 1,067
Tan, D.-X., Reiter, R., Manchester, L., Yan, M.-T., El-Sawi, M., Sainz, R., Mayo, J., Kohen, R., Allegra, M., & Hardelan, R. (2002) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026023394443 · Cited by 1,065
Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model
Kaspar, B. K., Lladó, J., Sherkat, N., Rothstein, J. D., & Gage, F. H. (2003) · Science · doi:10.1126/science.1086137 · Cited by 872
Howland, D. S., Liu, J., She, Y., Goad, B., Maragakis, N. J., Kim, B., Erickson, J., Kulik, J., DeVito, L., Psaltis, G., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.032539299 · Cited by 841
Oxidative damage in the central nervous system: protection by melatonin
Reiter, R. J. (1998) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00052-5 · Cited by 838
Evidence of Increased Oxidative Damage in Both Sporadic and Familial Amyotrophic Lateral Sclerosis
Ferrante, R. J., Browne, S. E., Shinobu, L. A., Bowling, A. C., Baik, M. J., MacGarvey, U., Kowall, N. W., Brown, R. H., & Beal, M. F. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69052064.x · Cited by 808
Beal, M. F. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00780-3 · Cited by 763 · cited 3×
“We note that similar to ALS, elevated tissue protein carbonyls have been detected inAlzheimer’s and Parkinson’s disease [37], but the causal role of ROS in the progression of these diseases is less clear.”
BackgroundAltered Reactivity of Superoxide Dismutase in Familial Amyotrophic Lateral Sclerosis
Wiedau-Pazos, M., Goto, J. J., Rabizadeh, S., Gralla, E. B., Roe, J. A., Lee, M. K., Valentine, J. S., & Bredesen, D. E. (1996) · Science · doi:10.1126/science.271.5248.515 · Cited by 719
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Nature Medicine · doi:10.1038/6568 · Cited by 682
Gurney, M. E., Cutting, F. B., Zhai, P., Doble, A., Taylor, C. P., Andrus, P. K., & Hall, E. D. (1996) · Annals of Neurology · doi:10.1002/ana.410390203 · Cited by 645
Williamson, T. L., & Cleveland, D. W. (1999) · Nature Neuroscience · doi:10.1038/4553 · Cited by 637
Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis
Rothstein, J. D., Tsai, G., Kuncl, R. W., Clawson, L., Cornblath, D. R., Drachman, D. B., Pestronk, A., Stauch, B. L., & Coyle, J. T. (1990) · Annals of Neurology · doi:10.1002/ana.410280106 · Cited by 636
Bowling, A. C., Schulz, J. B., Brown, R. H., & Beal, M. F. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb07478.x · Cited by 630
VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model
Azzouz, M., Ralph, G. S., Storkebaum, E., Walmsley, L. E., Mitrophanous, K. A., Kingsman, S. M., Carmeliet, P., & Mazarakis, N. D. (2004) · Nature · doi:10.1038/nature02544 · Cited by 590
Direct radioimmunoassay for melatonin in plasma.
Fraser, S., Cowen, P., Franklin, M., Franey, C., & Arendt, J. (1983) · Clinical Chemistry · doi:10.1093/clinchem/29.2.396 · Cited by 578
RNA editing and death of motor neurons
Kawahara, Y., Ito, K., Sun, H., Aizawa, H., Kanazawa, I., & Kwak, S. (2004) · Nature · doi:10.1038/427801a · Cited by 536
Melatonin mitigates mitochondrial malfunction
León, J., Acuña‐Castroviejo, D., Escames, G., Tan, D., & Reiter, R. J. (2005) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2004.00181.x · Cited by 514
Ralph, G. S., Radcliffe, P. A., Day, D. M., Carthy, J. M., Leroux, M. A., Lee, D. C. P., Wong, L.-F., Bilsland, L. G., Greensmith, L., Kingsman, S. M., et al. (2005) · Nature Medicine · doi:10.1038/nm1205 · Cited by 506
Raoul, C., Abbas-Terki, T., Bensadoun, J.-C., Guillot, S., Haase, G., Szulc, J., Henderson, C. E., & Aebischer, P. (2005) · Nature Medicine · doi:10.1038/nm1207 · Cited by 464
Julien, J.-P. (2001) · Cell · doi:10.1016/s0092-8674(01)00244-6 · Cited by 434
Rakhit, R., Crow, J. P., Lepock, J. R., Kondejewski, L. H., Cashman, N. R., & Chakrabartty, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313295200 · Cited by 344
Increased lipid peroxidation in sera of ALS patients: A potential biomarker of disease burden
Simpson, E. P., Henry, Y. K., Henkel, J. S., Smith, R. G., & Appel, S. H. (2004) · Neurology · doi:10.1212/wnl.62.10.1758 · Cited by 327
Minocycline delays disease onset and mortality in a transgenic model of ALS
Van Den Bosch, L., Tilkin, P., Lemmens, G., & Robberecht, W. (2002) · Neuroreport · doi:10.1097/00001756-200206120-00018 · Cited by 296
Cellular circadian clocks in the pineal
Falcón, J. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00078-1 · Cited by 293
A clinical trial of creatine in ALS
Shefner, J. M., Cudkowicz, M. E., Schoenfeld, D., Conrad, T., Taft, J., Chilton, M., Urbinelli, L., Qureshi, M., Zhang, H., Pestronk, A., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000142992.81995.f0 · Cited by 293
Guo, H. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg267 · Cited by 284
Desnuelle, C., Dib, M., Garrel, C., & Favier, A. (2001) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/146608201300079364 · Cited by 264
Almer, G., Vukosavic, S., Romero, N., & Przedborski, S. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0722415.x · Cited by 231
Cleveland, D. W. (1999) · Neuron · doi:10.1016/s0896-6273(00)81108-3 · Cited by 227
Benefit of valproic acid in suppressing disease progression of ALS model mice
Sugai, F., Yamamoto, Y., Miyaguchi, K., Zhou, Z., Sumi, H., Hamasaki, T., Goto, M., & Sakoda, S. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03765.x · Cited by 214
Graf, M., Ecker, D., Horowski, R., Kramer, B., Riederer, P., Gerlach, M., Hager, C., Ludolph, A. C., Kramer, B., Ecker, D., et al. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-004-0220-1 · Cited by 192
Transgenic mouse models of Alzheimer's disease
Janus, C., & Westaway, D. (2001) · Physiology & Behavior · doi:10.1016/s0031-9384(01)00524-8 · Cited by 176
Vitamin E intake and risk of amyotrophic lateral sclerosis
Ascherio, A., Weisskopf, M. G., O'Reilly, E. J., Jacobs, E. J., McCullough, M. L., Calle, E. E., Cudkowicz, M., & Thun, M. J. (2005) · Annals of Neurology · doi:10.1002/ana.20316 · Cited by 165
First‐Time‐in‐Human Dose Selection: Allometric Thoughts and Perspectives
Boxenbaum, H., & DiLea, C. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04011.x · Cited by 161
Ubiquitous melatonin-presence and effects in unicells, plants and animals
Hardeland, R., & Fuhrberg, B. (1996) · Cited by 147
Self-citationPompl, P. N., Ho, L., Bianchi, M., McManus, T. E., Qin, W., & Pasinetti, G. M. (2003) · The FASEB Journal · doi:10.1096/fj.02-0876fje · Cited by 144
Efficient three‐drug cocktail for disease induced by mutant superoxide dismutase
Križ, J., Gowing, G., & Julien, J. (2003) · Annals of Neurology · doi:10.1002/ana.10500 · Cited by 142
Vanselow, B. K., & Keller, B. U. (2000) · The Journal of Physiology · doi:10.1111/j.1469-7793.2000.t01-1-00433.x · Cited by 132
Transport of Albumin‐bound Melatonin Through the Blood‐Brain Barrier
Pardridge, W. M., & Mietus, L. J. (1980) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1980.tb11272.x · Cited by 124
Development and characterisation of a glutamate-sensitive motor neurone cell line
Eggett, C. J., Crosier, S., Manning, P., Cookson, M. R., Menzies, F. M., McNeil, C. J., & Shaw, P. J. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741895.x · Cited by 111 · cited 2×
“To differentiate NSC-34 cells into a motoneuronal and glutamate-responsive phenotype [28], DMEM was replaced by DMEM/Ham’s F12 supplemented by 1% FCS, 1% penicillin/streptomycin and 1% modified Eagle’s medium nonessential amino acids.”
MethodParvalbumin is a marker of ALS-resistant motor neurons
Elliott, J. L., & Snider, W. D. (1995) · Neuroreport · doi:10.1097/00001756-199502000-00011 · Cited by 103
Tang, Y. P., Ma, Y., Chao, C.-C., Chen, K. Y., & Lee, E. H. Y. (1998) · Journal of Neuroscience Research · Cited by 96
Nagano, S., Fujii, Y., Yamamoto, T., Taniyama, M., Fukada, K., Yanagihara, T., & Sakoda, S. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(02)00014-6 · Cited by 83
Jacob, S., Pöeggeler, B., Weishaupt, J. H., Sirén, A., Hardeland, R., Bähr, M., & Ehrenreich, H. (2002) · Journal of Pineal Research · doi:10.1034/j.1600-079x.2002.02943.x · Cited by 81
Self-citationOxidative damage to proteins in the spinal cord in amyotrophic lateral sclerosis (ALS).
Niebrój-Dobosz, I., Dziewulska, D., & Kwieciński, H. (2004) · PubMed · Cited by 60
The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis
Bensimon, G., & Doble, A. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.6.525 · Cited by 54
Antioxidant treatment for amyotrophic lateral sclerosis / motor neuron disease
Orrell, R. W., Lane, R., & Ross, M. A. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002829.pub3 · Cited by 36
Cited by
Oxidative Stress in Neurodegenerative Diseases
Simonian, N. A., & Coyle, J. T. (1996) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.36.040196.000503 · Cited by 1,377
Autophagy and apoptosis dysfunction in neurodegenerative disorders
Ghavami, S., Shojaei, S., Yeganeh, B., Ande, S. R., Jangamreddy, J. R., Mehrpour, M., Christoffersson, J., Chaabane, W., Moghadam, A. R., Kashani, H. H., et al. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.10.004 · Cited by 1,039
Melatonin—A pleiotropic, orchestrating regulator molecule
Hardeland, R., Cardinali, D. P., Srinivasan, V., Spence, D. W., Brown, G. M., & Pandi-Perumal, S. R. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.12.004 · Cited by 843
Self-citationOxidative Stress in Neurodegenerative Diseases
Niedzielska, E., Smaga, I., Gawlik, M., Moniczewski, A., Stankowicz, P., Pera, J., & Filip, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9337-5 · Cited by 800
Bioinorganic Chemistry of Alzheimer’s Disease
Kepp, K. P. (2012) · Chemical Reviews · doi:10.1021/cr300009x · Cited by 672
Metadata
- Authors
- Weishaupt, J. H., Bartels, C., Pölking, E., Dietrich, J., Rohde, G., Poeggeler, B., Mertens, N., Sperling, S., Bohn, M., Hüther, G., Schneider, A., Bach, A., Sirén, A., Hardeland, R., Bähr, M., Nave, K., & Ehrenreich, H.
- Venue
- Journal of Pineal Research
- Publisher
- Wiley
- Published
- 2006-08-29
- Volume
- 41
- Issue
- 4
- Pages
- 313-323
- ISSN
- 0742-3098 (ISSN-L)
- 1600-079X
- OpenAlex
- W2113208927
- Cited by
- 282
- References
- 61
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.